Table 1.

Characteristics of Randomized Controlled Trials of Cognitive Behavioral Therapy (CBT) and Serotonin Reuptake Inhibitores (SRIs) Included in Meta-analysis

	N	Treatment Subtype	Control Tx	Mean Age	% Comorbid TS/CTD	% Comorbid ADHD	% Comorbid Depressive Disorder	% Comorbid Anxiety Disorder	Baseline OCD Severity on CY-BOCS	% on SRI Med at Baseline	# of 1hr Therapy Sessions	% Active Tx Dropout	Method Quality
CBT Trials
Barrett et al. 2004	48	ERP	WL	11.3	23	0	2	77	23.3	17	14	0	29
POTS, 2004a	56	ERP	PLBO	11.9	14	16	7	29	25.6	0	14	11	38
Bolton & Perrin, 2007	20	ERP	WL	13.2	5	5	10	50	23.0	0	9	20	30
Freeman et al. 2008	42	ERP	RT	7.1	10	19	NR	NR	22.4	14	12	27	32
Williams et al. 2010	21	CT	WL	13.6	NR	10	5	NR	22.1	33	10	9	31
Bolton et al. 2011	60	CT	WL	14.6	3	8	15	38	23.1	15	12	6	31
Piacentini et al. 2011	71	ERP	RT	12.2	11	14	4	47	24.9	9	12	16	38
Storch et al. 2011	31	ERP	WL	11.1	3	7	10	45	23.4	55	14	13	31
Lewin et al. 2014	31	ERP	TAU	5.8	0	42	0	71	24.5	0	12	0	32
Freeman et al. 2014	127	ERP	RT	7.2	18	14	2	47	25.6	2	12	13	41
SRI Trials
Flament et al. 1985b	19	CMI	WL	14.5	NR	NR	NR	NR	NR	0	NA	0	33
Leonard et al. 1989b	49	CMI	DES	13.9	NR	NR	NR	NR	NR	0	NA	2	28
March et al. 1990c	16	CMI	PLBO	15.0	0	NR	NR	NR	26.0	0	NA	25	26
DeVeaugh-Geiss et al. 1992c	60	CMI	PLBO	14.3	0	0	NR	NR	27.7	0	NA	13	31
Riddle et al. 1992	13	FLUX	PLBO	11.7	15	8	15	54	22.4	0	NA	14	36
March et al. 1998	107	SERT	PLBO	12.6	4	5	2	4	22.8	0	NA	20	34
Geller et al. 2001c	103	FLUX	PLBO	11.4	0	0	NR	NR	25.0	0	NA	31	37
Riddle et al. 2001	120	FLUV	PLBO	13.0	NR	2	1	2	24.2	0	NA	33	33
Liebowietz et al. 2002c	43	FLUX	PLBO	12.7	0	7	21	47	23.2	0	NA	5	39
Geller et al. 2004	203	PARX	PLBO	11.3	NR	9	NR	7	24.8	0	NA	34	39
POTS, 2004a	56	SERT	PLBO	12.0	18	16	7	34	23.4	0	NA	7	29

^aplacebo group used in both comparisons,

^bused a cross-over trial design,

^cTourette Syndrome in exclusion criteria

NOTE: NR = Not Reported, NA = Not Available/Applicable